Prof. Dr. Hans-Jürgen Wester
Academic Career and Research Areas
Prof. Wester’s (*1962) research focuses on the development of targeted radiolabelled probes and therapeutics (radiopharmaceuticals) for molecular imaging and targeted radioligand therapy. He has developed several methodological procedures and radiopharmaceuticals for oncological, neurological and cardiovascular investigations and therapies that have found broad application in clinical investigations and therapies.
After studying chemistry at the University of Cologne, he carried out his doctoral research at the Research Center Juelich, received his doctoral degree in Nuclear Chemistry/Radiopharmaceutical Chemistry (1995). After joining the Dept. of Nuclear Medicine at the Klinikum r.d. Isar, TUM, he served as a research assistant in 2000 and associate professor in the School of Medicine in 2004. Since 2010, Prof. Wester is Full Professor and holds the Chair of Pharmaceutical Radiochemistry (Department of Chemistry and School of Medicine). He has declined numerous appointments at foreign universities (e.g. University of Alabama at Birmingham and University of Pennsylvania (USA), Helmholtz-Zentrum Dresden-Rossendorf).
Key Publications (all publications)
Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ: "[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent". Theranostics. 2017; 7(9): 2350-2362.
AbstractRobu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ: "Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer". The Journal of Nuclear Medicine. 2017; 58(2): 235-242.
AbstractBaum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ: "177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy". The Journal of Nuclear Medicine. 2016; 57(7): 1006-1013.
AbstractWester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M: "Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging". Theranostics. 2015; 5(6): 618-30.
AbstractWester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G: "Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging". The Journal of Nuclear Medicine. 1999; 40(1): 205-212.
Abstract